Loring Wolcott & Coolidge Fiduciary Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$461K	Hold	1,533	–	–	﹤0.01%	241
2026 Q1	$494K	Hold	1,533	–	–	﹤0.01%	235
2025 Q4	$544K	Hold	1,533	–	–	﹤0.01%	232
2025 Q3	$711K	Hold	1,533	–	–	0.01%	203
2025 Q2	$500K	Hold	1,533	–	–	﹤0.01%	211
2025 Q1	$371K	Hold	1,533	–	–	﹤0.01%	227
2024 Q4	$424K	Sell	1,533 -257	-14%	-$67.6K	﹤0.01%	224
2024 Q3	$526K	Sell	1,790 -115	-6%	-$29.9K	﹤0.01%	211
2024 Q2	$476K	Hold	1,905	–	–	﹤0.01%	210
2024 Q1	$278K	Hold	1,905	–	–	﹤0.01%	244
2023 Q4	$329K	Hold	1,905	–	–	﹤0.01%	229
2023 Q3	$308K	Sell	1,905 -60	-3%	-$11.4K	﹤0.01%	236
2023 Q2	$373K	Hold	1,965	–	–	﹤0.01%	232
2023 Q1	$394K	Hold	1,965	–	–	﹤0.01%	217
2022 Q4	$467K	Hold	1,965	–	–	0.01%	199
2022 Q3	$393K	Hold	1,965	–	–	0.01%	219
2022 Q2	$287K	Sell	1,965 -60	-3%	-$8.51K	﹤0.01%	252
2022 Q1	$331K	Hold	2,025	–	–	﹤0.01%	244
2021 Q4	$343K	Hold	2,025	–	–	﹤0.01%	248
2021 Q3	$382K	Sell	2,025 -17	-0.8%	-$3.19K	﹤0.01%	236
2021 Q2	$346K	Sell	2,042 -5	-0.2%	-$732	﹤0.01%	256
2021 Q1	$289K	Buy	2,047 +22	+1%	+$3.31K	﹤0.01%	257
2020 Q4	$263K	Hold	2,025	–	–	﹤0.01%	259
2020 Q3	$295K	Hold	2,025	–	–	﹤0.01%	233
2020 Q2	$300K	Hold	2,025	–	–	﹤0.01%	217
2020 Q1	$220K	Hold	2,025	–	–	﹤0.01%	229
2019 Q4	$233K	Hold	2,025	–	–	﹤0.01%	262
2019 Q3	$163K	Hold	2,025	–	–	﹤0.01%	284
2019 Q2	$147K	Hold	2,025	–	–	﹤0.01%	289
2019 Q1	$189K	Hold	2,025	–	–	﹤0.01%	261
2018 Q4	$148K	Sell	2,025 -6,005	-75%	-$462K	﹤0.01%	279
2018 Q3	$703K	Hold	8,030	–	–	0.01%	182
2018 Q2	$791K	Hold	8,030	–	–	0.01%	175
2018 Q1	$956K	Hold	8,030	–	–	0.02%	164
2017 Q4	$1.02M	Sell	8,030 -245	-3%	-$30.8K	0.02%	166
2017 Q3	$972K	Hold	8,275	–	–	0.02%	161
2017 Q2	$685K	Hold	8,275	–	–	0.01%	172
2017 Q1	$424K	Hold	8,275	–	–	0.01%	200
2016 Q4	$310K	Hold	8,275	–	–	0.01%	227
2016 Q3	$561K	Sell	8,275 -315	-4%	-$22.2K	0.01%	184
2016 Q2	$477K	Hold	8,590	–	–	0.01%	189
2016 Q1	$539K	Hold	8,590	–	–	0.01%	180
2015 Q4	$809K	Sell	8,590 -4,215	-33%	-$391K	0.02%	163
2015 Q3	$1.53M	Hold	12,805	–	–	0.04%	127
2015 Q2	$1.53M	Sell	12,805 -2,305	-15%	-$275K	0.04%	127
2015 Q1	$1.58M	Sell	15,110 -1,055	-7%	-$107K	0.04%	127
2014 Q4	$1.57M	Hold	16,165	–	–	0.04%	125
2014 Q3	$1.26M	Hold	16,165	–	–	0.03%	133
2014 Q2	$1.02M	Sell	16,165 -150	-0.9%	-$8.92K	0.03%	148
2014 Q1	$1.09M	Sell	16,315 -1,660	-9%	-$129K	0.03%	145
2013 Q4	$1.16M	Sell	17,975 -3,375	-16%	-$201K	0.03%	138
2013 Q3	$1.37M	Sell	21,350 -1,925	-8%	-$96K	0.04%	126
2013 Q2	$722K	Buy	+23,275	New	+$619K	0.02%	165

Other funds holding ALNY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's ALNY Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,533 shares worth $461K. The position accounts for ﹤0.01% of the portfolio, ranked #241.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.58M in Q1 2015. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 1,533 shares of Alnylam Pharmaceuticals worth $461K as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #241 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Alnylam Pharmaceuticals position peaked at $1.58M in Q1 2015.
365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.